National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 52 of 66
Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
NCT00049569
SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
NCT00052897
Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer
NCT00052728
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
NCT00053937
Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
NCT00052689
Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
NCT00054028
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
NCT00054132
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
NCT00039494
Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma
NCT00053950
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
NCT00054405
Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
NCT00042796
Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer
NCT00339651
Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein
NCT00048880
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
NCT00033618
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
NCT00049192
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
NCT00039481
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
NCT00048893
Depsipeptide to Treat Thyroid and Other Advanced Cancers
NCT00048334
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
NCT00052780
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
NCT00022737
Gefitinib in Treating Patients With Cervical Cancer
NCT00049556
Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer
NCT00049166
Validation of Self-Reported Needle Sharing Among Injection Drug Users
NCT00341081
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
NCT00047879
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
NCT00055770
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
NCT00045708
Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
NCT00045565
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
NCT01989559
Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors
NCT00054548
Brachytherapy in Treating Patients With Recurrent Malignant Glioma
NCT00045474
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
NCT00052585
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
NCT00043979
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
NCT00049283
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00052338
Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00047203
Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
NCT00052351
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT00049387
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT02227901
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
NCT00053963
Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
NCT00030394
Oxaliplatin in Treating Patients With Liver Cancer
NCT00052364
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
NCT00052377
National Lung Screening Trial (NLST) Screening
NCT00047385
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
NCT00045110
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
NCT00047047
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
NCT00045227
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
NCT00047190
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
NCT00047346
UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00042861
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
NCT00021060
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.